Image pharmaphorum Editor Podcasts The future biosimilar landscape: the pharmaphorum podcast For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the compa Debates & Insight Sponsored Can simulated datasets unlock the potential of patient data? Overview Views & Analysis Strategic planning in increasingly complex and uncertain mar... This article is the first in a series of three from Osprey Health Consulting that address the contemporary challenges facing strategic brand planners dealing with increasingly complex and uncertain News Amgen invests £50m in UK genetics firm Oxford Nanopore Biotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its cutting-edge technology. Load more results
Podcasts The future biosimilar landscape: the pharmaphorum podcast For episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet the head of the compa
Views & Analysis Strategic planning in increasingly complex and uncertain mar... This article is the first in a series of three from Osprey Health Consulting that address the contemporary challenges facing strategic brand planners dealing with increasingly complex and uncertain
News Amgen invests £50m in UK genetics firm Oxford Nanopore Biotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its cutting-edge technology.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
